The tariff war and COVID-19 exacerbated pre-existing fragility of global supply chains for many industries. This fragility is especially prevalent in the bioscience and pharma sectors, where China supplies 40% of all Active Pharmaceutical Ingredients (APIs) globally and, where India supplies 75% to 80% of APIs to the U.S.
For antibiotics in particular, global supply chains have been negatively impacted as a result of COVID-19-related disruptions. As essential components of pandemic preparedness, antibiotics and other medicines are vital to national security. Yet, China supplies the majority of generic antibiotics on which we rely.
We are therefore seeing a clear movement within the bioscience and pharma industries toward securing redundant and localized supply chains for ingredients and medicines that are essential to the health and well-being of society. https://www.lifescienceleader.com/doc/ceos-weigh-in-on-the-supply-chain-nationalism-and-the-reshoring-of-biopharma-manufacturing-0001